Compare Analog Devices, Inc. (ADI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Analog Devices, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Analog Devices, Inc. trades at $386.31 (market cap $184.62B), while Ginkgo Bioworks Holdings Inc trades at $8.89 (market cap $610.13M). The key difference: Analog Devices, Inc. is far larger — about 302.6× Ginkgo Bioworks Holdings Inc's market cap, and Analog Devices, Inc. pays a 1.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| ADI | DNA | |
|---|---|---|
Market Cap | $184.62B | $610.13M |
Sector | Technology | Health |
52-Week High | $445.48 | $16.14 |
52-Week Low | $220.68 | $5.48 |
Enterprise Value | $189.87B | $647.37M |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $379.03, up 0.5% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q3-Q1 2026) and robust profitability (26% net margin). Recent acquisition of Empower Semiconductor and AI-driven semiconductor demand provide growth catalysts. Cash flow remains positive at $508M in 2025, though net cash flow is projected to decline to $61M in 2026.
Outlook remains positive with 79.6% analyst buy ratings and $471 consensus price target (24% upside). Key risks include elevated valuation multiples (P/E 57.9) and debt-to-asset ratio increase to 17.9%. The stock offers dividend income ($1.10 H1-26) while benefiting from semiconductor industry tailwinds, though margin sustainability and competitive pressures warrant monitoring.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
